Premium
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies
Author(s) -
Girmenia Corrado,
Lazzarotto Tiziana,
Bonifazi Francesca,
Patriarca Francesca,
Irrera Giuseppe,
Ciceri Fabio,
Aversa Franco,
Citterio Franco,
Cillo Umberto,
Cozzi Emanuele,
Gringeri Enrico,
Baldanti Fausto,
Cavallo Rossana,
Clerici Pierangelo,
Barosi Giovanni,
Grossi Paolo
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13666
Subject(s) - medicine , serostatus , intensive care medicine , cytomegalovirus , transplantation , hematopoietic stem cell transplantation , hematopoietic cell , immunology , organ transplantation , stem cell , herpesviridae , human immunodeficiency virus (hiv) , viral disease , haematopoiesis , biology , genetics , viral load
Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and solid organ transplantation (SOT) recipients. In view of the uncertainties on the assessment and prevention of CMV infection in both transplant procedures, three Italian scientific societies for HSCT and SOT and for Clinical Microbiology appointed a panel of experts to compose a framework of recommendations. Recommendations were derived from a comprehensive analysis of the scientific literature and from a multidisciplinary consensus conference process. The lack of adequate clinical trials focused on certain diagnostic procedures, and antiviral intervention forced the panel to use the methods of consensus for shaping some recommendations. Recommendations concerning the two types of transplant were given for the following issues: assessment of pretransplant CMV serostatus, immunological monitoring after transplant, CMV prophylaxis with antivirals, CMV preemptive strategy, and CMV prophylaxis with immunoglobulin infusion and with adoptive immunotherapy. The questions raised by and the recommendations resulting from this consensus conference project may contribute to the improvement of certain crucial aspects of the management of CMV infections in allo‐HSCT and in SOT populations.